Publication at First Faculty of Medicine |
2018
Abstract
This case report describes a female patient who was diagnosed at the age of 11 with Crohn's disease with ileocecal and perianal localization. The disease course was progressive, and conventional therapy was ineffective.
The patient did not tolerate long-term treatment with anti-TNF antibodies. Next, therapy with an anti-integrin antibody was given, which had some efficacy for the luminal disease, but none for the perianal disease.
Therefore, in June, 2017, we initiated therapy with ustekinumab. The patient responded within 6 weeks, with clear improvement of bowel symptoms as well as perianal disease.
We have not observed any adverse effects of ustekinumab in this patient.